Paul Grayson, Tentarix CEO (Versant)
October 15, 2021 08:35 AM EDT
Financing

Phar­ma vet­er­ans re­group with $50M and a plan to dis­cov­er new mul­ti-specifics

Nicole DeFeudis

Editor

While a horde of drug­mak­ers de­vel­ops bis­pe­cif­ic an­ti­bod­ies to more di­rect­ly tar­get tu­mor cells — there were about 100 pro­grams in or near­ing clin­i­cal tri­als …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times